APPLICATION OF THE REAL – TIME PCR FOR THE DETECTION OF CYP2C19*2 SINGLE NUCLEOTIDE POLYMORPHISM IN PATIENS WITH GASTRITIS AT TRA VINH GENERAL HOSPITAL
Keywords:
CYP2C19*2, single nucleotide polymorphism, real - time PCR, gastritis
Abstract
The aim of this study is to identify CYP2C19*2 single nucleotide polymorphisms in patients with gastritis at TraVinh General Hospital. A cross-sectional study was conducted in 280 endoscopic gastric biopsy samples of patients with gastritis at TraVinh General Hospital. CYP2C19*2 genotypes were determined by realtime PCR method using TaqMan probes. Data were stored and analyzed by IBM SPSS Statistic (version 20.0; Armonk, New York, USA) and Excel 2010. The prevallelece of GG, AG and AA genotypes were 51.8, 39.6 and 8.6% correspondingly. The ratio of allele G and A were 0.716 and 0.284 respectively. The correlation of CYP2C19*2 polymorphisms with age (p=0.891), gender (p=0.652) was not significantly distinguished
Downloads
Download data is not yet available.
References
[1] Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL,
Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19
genotype and clopidogrel therapy: 2013 update. Clin
Pharmacol Ther. 2013;94(3):317–323.
[2] Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS,
Thorn CF, Altman RB, et al. PharmGKB summary: very important pharmacogene information for
cytochrome P450, family 2, subfamily C, polypeptide
19. Pharmacogenet Genomics. 2012;22(2):159–165.
[3] Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with
DNA polymerase. J Mol Biol. 1975;94(4):441–448.
[4] Altay C, Orhan K, Hakan S, Cem A, Bura Tolga K,
Omer F, et al. The prevallelece of CYP2C19 mutations in Turkish patients with dyspepsia. Turk J
Gastroenterol. 2009;20(3):161–164.
[5] Morton J Kern, Arnold H Seto, Charles M Parise. Antithrombotic and Antiplatelet Therapy for Percutaneous
Coronary Interventions. Morton J Kern, The Cardiac
Catheterization Handbook, Elsevier Saunders, Philadenphia. 2013.
[6] Muller ¨ I, Besta F, Schulz C, Massberg S, Schonig ¨ A,
Gawaz M. Prevallelece of clopidogrel non-responders
among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb
Haemost. 2003;89(5):783–778.
[7] Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS,
et al. Comparisons of CYP2C19 Genetic Polymorphisms Between Korean and Vietnamese Populations.
Therapeutic Drug Monitoring. 2007;29(4):455–459.
[8] Anca D Buzoianu, Adrian P Trifa, Radu A Popp,
Mariela S Militaru, Claudia F Militaru, Corina I Bocsan, et al. Screening for CYP2C19*2, *3 and *4
gene variants in a Romanian population study group.
Farmacia. 2010;58(6).
[9] Yu Chen, Xiaohong Huang, Yong Tang, Yuquan Xie,
Yachen Zhang. Both PON1 QQ192R and
CYP2C19*2 influence platelet reponse to clopidogrel
and ischemic events in Chinese patients undergoing
percuteaneous coronary intervention. Int J Clin Exp
Med. 2015;8(6):9266–9274.
[10] Hui-Lin Tang, Yan Li, Yong-Fang Hu, HongGuang Xie, Suo-Di Zhai. Effects of CYP2C19 lossof-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitorbased triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013;8(4):62162.
[11] Ngô Anh Duy, Nguyễn Tuấn Anh, Trần Thiện Trung.
Tối ưu hóa quy trình real-time PCR phát hiện SNP
CYP2C19*2. Tạp chí Y học Thành phố Hồ Chí Minh.
2017;21(5):173–181.
[12] Veiga MI, Asimus S, Ferreira PE, Martins JP,
Cavaco I, Ribeiro V, et al. Pharmacogenomics of
CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4,
CYP3A5 and MDR1 in Vietnam. Eur J ClinPharmacol. 2009;65(4):63–355.
4
Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19
genotype and clopidogrel therapy: 2013 update. Clin
Pharmacol Ther. 2013;94(3):317–323.
[2] Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS,
Thorn CF, Altman RB, et al. PharmGKB summary: very important pharmacogene information for
cytochrome P450, family 2, subfamily C, polypeptide
19. Pharmacogenet Genomics. 2012;22(2):159–165.
[3] Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with
DNA polymerase. J Mol Biol. 1975;94(4):441–448.
[4] Altay C, Orhan K, Hakan S, Cem A, Bura Tolga K,
Omer F, et al. The prevallelece of CYP2C19 mutations in Turkish patients with dyspepsia. Turk J
Gastroenterol. 2009;20(3):161–164.
[5] Morton J Kern, Arnold H Seto, Charles M Parise. Antithrombotic and Antiplatelet Therapy for Percutaneous
Coronary Interventions. Morton J Kern, The Cardiac
Catheterization Handbook, Elsevier Saunders, Philadenphia. 2013.
[6] Muller ¨ I, Besta F, Schulz C, Massberg S, Schonig ¨ A,
Gawaz M. Prevallelece of clopidogrel non-responders
among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb
Haemost. 2003;89(5):783–778.
[7] Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS,
et al. Comparisons of CYP2C19 Genetic Polymorphisms Between Korean and Vietnamese Populations.
Therapeutic Drug Monitoring. 2007;29(4):455–459.
[8] Anca D Buzoianu, Adrian P Trifa, Radu A Popp,
Mariela S Militaru, Claudia F Militaru, Corina I Bocsan, et al. Screening for CYP2C19*2, *3 and *4
gene variants in a Romanian population study group.
Farmacia. 2010;58(6).
[9] Yu Chen, Xiaohong Huang, Yong Tang, Yuquan Xie,
Yachen Zhang. Both PON1 QQ192R and
CYP2C19*2 influence platelet reponse to clopidogrel
and ischemic events in Chinese patients undergoing
percuteaneous coronary intervention. Int J Clin Exp
Med. 2015;8(6):9266–9274.
[10] Hui-Lin Tang, Yan Li, Yong-Fang Hu, HongGuang Xie, Suo-Di Zhai. Effects of CYP2C19 lossof-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitorbased triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013;8(4):62162.
[11] Ngô Anh Duy, Nguyễn Tuấn Anh, Trần Thiện Trung.
Tối ưu hóa quy trình real-time PCR phát hiện SNP
CYP2C19*2. Tạp chí Y học Thành phố Hồ Chí Minh.
2017;21(5):173–181.
[12] Veiga MI, Asimus S, Ferreira PE, Martins JP,
Cavaco I, Ribeiro V, et al. Pharmacogenomics of
CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4,
CYP3A5 and MDR1 in Vietnam. Eur J ClinPharmacol. 2009;65(4):63–355.
4
Published
01-December-2018
How to Cite
1.
Ngo D, Tran T, Nguyen A, Nguyen T. APPLICATION OF THE REAL – TIME PCR FOR THE DETECTION OF CYP2C19*2 SINGLE NUCLEOTIDE POLYMORPHISM IN PATIENS WITH GASTRITIS AT TRA VINH GENERAL HOSPITAL. journal [Internet]. 1Dec.2018 [cited 22Dec.2024];8(32):39-3. Available from: https://journal.tvu.edu.vn/tvujs_old/index.php/journal/article/view/57
Section
Articles
